

Cover Story
Conversation with The Cancer Letter
By Matthew Bin Han Ong
It's fair to say that eight years ago, when the Obama administration infused the economy with $800 billion in stimulus funding, policymakers likely did not expect the health information technology industry to evolve into fiefdoms guarded by legions of lawyers and walls of proprietary code.
By Matthew Bin Han Ong
In Brief


Drugs & Targets


Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- CBER Director Vinay Prasad dared to “say no to drugs”
- Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC











